ORTX News and Press, Orchard Therapeutics plc From 12/29/21

Cantor Fitzgerald analyst Pete Stavropoulos assumed coverage of Orchard Therapeutics (NASDAQ:ORTX) with an Overweight rating with a price target (PT) of $9, down from $12. Shares up 10% premarket $1.19. PT of $9 implies a premium of ~656.3% to the last close. Orchard is de...

ShiftPixy (NASDAQ:PIXY) +53%. MingZhu Logistics Holdings (NASDAQ:YGMZ) +44% on share purchase agreement to acquire CheYi Network. Pop Culture Group (NASDAQ:CPOP) +17%. Can-Fite BioPharma (NYSE:CANF) +17% to file for patents after new findings for liver cancer therapy. Orch...

The Nasdaq Biotechnology Index will have a new look on December 20, before the market opens when 129 securities will be added and 21 securities will be deleted as part of the annual reconstitution. Notable additions to the index: Viatris (NASDAQ:VTRS), NovoCure (NASDAQ:NVCR), Anavex Life Scie...

Dicerna Pharmaceuticals DRNA +78% Novo Nordisk agrees to acquire Dicerna for more than $3 billion Cardiff Oncology (NASDAQ:CRDF) +23% announces $15M equity investment from Pfizer through its Pfizer breakthrough growth initiative Cloopen Group Holding RAAS +19% on Q3 result...

100 percent overall survival with median follow-up of two years post-treatment with HSC gene therapy Preliminary findings show promising metabolic and early clinical outcomes Results warrant further evaluation in global registrational study expected to be initiated in 20...

BOSTON and LONDON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present and be available for one-on-one meetings at the following virtual investor conferences: Barclays G...

Orchard Therapeutics (NASDAQ:ORTX): Q3 GAAP EPS of -$0.29 misses by $0.04. Revenue of $1.19M (-40.5% Y/Y) misses by $3.61M. Press Release For further details see: Orchard Therapeutics EPS misses by $0.04, misses on revenue

Updates from OTL-201 Clinical Proof-of-Concept Study in MPS-IIIA and OTL-204 Preclinical Study for GRN-FTD at ESGCT Showcase Potential for HSC Gene Therapy in Multiple Neurodegenerative Disorders Launch Activities for Libmeldy® Across Key European Countries, including Reimb...

BOSTON and LONDON, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the acceptance of nine abstracts at the upcoming European Society of Gene & Cell Therapy Congress (ESGCT) taking place virtually from October 19-22. ...

The following slide deck was published by Orchard Therapeutics plc in conjunction with this event. For further details see: Orchard Therapeutics (ORTX) Investor Prentation - Slideshow